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Abstract
The Italian College of Breast Radiologists by the Italian Society of Medical Radiology (SIRM) provides recommendations 
for breast care provision and procedural prioritization during COVID-19 pandemic, being aware that medical decisions must 
be currently taken balancing patient’s individual and community safety: (1) patients having a scheduled or to-be-scheduled 
appointment for in-depth diagnostic breast imaging or needle biopsy should confirm the appointment or obtain a new one; (2) 
patients who have suspicious symptoms of breast cancer (in particular: new onset palpable nodule; skin or nipple retraction; 
orange peel skin; unilateral secretion from the nipple) should request non-deferrable tests at radiology services; (3) asymp-
tomatic women performing annual mammographic follow-up after breast cancer treatment should preferably schedule the 
appointment within 1 year and 3 months from the previous check, compatibly with the local organizational conditions; (4) 
asymptomatic women who have not responded to the invitation for screening mammography after the onset of the pandemic 
or have been informed of the suspension of the screening activity should schedule the check preferably within 3 months 
from the date of the not performed check, compatibly with local organizational conditions. The Italian College of Breast 
Radiologists by SIRM recommends precautions to protect both patients and healthcare workers (radiologists, radiographers, 
nurses, and reception staff) from infection or disease spread on the occasion of breast imaging procedures, particularly mam-
mography, breast ultrasound, breast magnetic resonance imaging, and breast intervention procedures.
Keywords COVID-19 · Breast care recommendations · Breast cancer · Priority categories · Personal protective equipment 
(PPE)
Introduction
At the beginning of February 2020, only three cases of coro-
navirus disease 2019 (COVID-19) were identified in Italy, all 
involving people who had recently travelled to China [1]. On 
February 20, 2020, a severe case of pneumonia due to severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
was diagnosed in Lombardy, Italy, in a man in his 30s with-
out any history of possible exposure abroad [2]. Within 
14 days, many other cases of COVID-19 in the surrounding 
area were diagnosed, including a substantial number of criti-
cally ill patients [3]. On March 9, 2020, the Italian Gov-
ernment implemented extraordinary measures to limit viral 
transmission restricting movement in the entire national 
territory to minimize potential contacts with infected peo-
ple (www.gover no.it, 2020). At that time, the total cases 
in Italy were 10,149 and the deaths more than 630 (www.
stati sta.com, 2020). Since then, a spread of COVID-19 was 
observed, especially in northern Italy, with a wide severity 
spectrum, ranging from asymptomatic disease, minor flu-
like symptoms to severe pneumopathies or multiorgan fail-
ure [3]. Italian case fatality rate [4], at the time of writing, 
was 14%, one of the highest worldwide (www.stati sta.com, 
2020). Patients who are older and have comorbidities (dia-
betes, cardiovascular disease, cancer, immunosuppression, 
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obesity, etc.) are the most likely to develop severe forms [5, 
6]. In Italy, as of May 13, 2020, there were 221,216 con-
firmed cases of COVID-19 and 30,911 related deaths (www.
stati sta.com, 2020).
COVID-19 pandemic imposed clinicians a unique set of 
challenges in the management of women needing periodi-
cal screening mammography, imaging, and/or needle biopsy 
for a suspect breast cancer. Because of the combination of 
lockdown, need of social distancing, and reduced hospi-
tal resources, in many cases the routine outpatient breast 
imaging activity has been drastically reduced. Therefore, 
it is crucial to define which women require urgent or non-
reschedulable care, can wait reasonable time, or can wait 
until the pandemic is over [7, 8]. A new paradigm has been 
introduced by the pandemic facing, on the one hand, with 
best oncological management, avoiding any potential loss of 
opportunity [9, 10] and, on the other, extra-protection from 
the risk of SARS-CoV-2 infection [11].
In this context, the Italian College of Breast Radiologists 
by the Italian Society of Medical Radiology (SIRM) pro-
vides recommendations for breast care provision and pro-
cedural prioritization, being aware that medical decisions 
must be currently taken balancing patient’s individual and 
community safety. These recommendations are limited to 
the diagnosis and management of breast malignant disease. 
Recommendations for oncologic imaging of whole-body 
staging/restaging are left to general oncologic imaging rec-
ommendations (www.esmo.org, 2020; www.asco.org, 2020) 
[11, 12].
Priority categories and suggested practice
The response to this pandemic has led to a sudden disruption 
of routine medical care, including breast imaging workup in 
asymptomatic population, symptomatic patients, and man-
agement of cancer patients [7, 8]. Even early breast cancer 
can be a fatal disease if left untreated, so adequate surgery 
combined with appropriate perioperative therapies is essen-
tial to improve the outcome [9, 10]. It is well known that 
early detection contributes to a decrease in specific breast 
cancer mortality [13–15], and breast cancer outcomes are 
dependent on timely and high-quality multidisciplinary 
interventions [14]. A short delay (e.g., 6–12 weeks) should 
not affect overall outcomes [9, 10], while a diagnostic delay 
longer than 3 months potentially does [9, 10]. Triage may 
become necessary to justify which patients should undergo 
immediate care versus further delay.
In this context, the Italian College of Breast Radiologists 
by SIRM has defined the following recommendations:
1. patients having a scheduled or to-be-scheduled appoint-
ment for in-depth diagnostic breast imaging or needle 
biopsy should confirm the appointment or obtain a new 
one;
2. patients who have suspicious symptoms of breast cancer 
(in particular: new onset palpable nodule; skin or nipple 
retraction; orange peel skin; unilateral secretion from the 
nipple) should request non-deferrable tests at radiology 
services;
3. asymptomatic women performing annual mammo-
graphic follow-up after breast cancer treatment should 
preferably schedule the appointment within 1 year and 
3 months from the previous check, compatibly with the 
local organizational conditions;
4. asymptomatic women who have not responded to the 
invitation for screening mammography after the onset 
of the pandemic or have been informed of the suspen-
sion of the screening activity should schedule the check 
preferably within 3 months from the date of the not 
performed check, compatibly with local organizational 
conditions.
These recommendations are driven by the common goal 
to preserve hospital resources for COVID-19 patients by 
deferring breast imaging procedures without compro-
mising long-term outcomes for individual patients. The 
demands COVID-19 pandemic will put on healthcare 
institutions remain unpredictable and will have temporal 
and geographical variability. Therefore, the risk of dis-
ease progression and compromised breast cancer-specific 
outcomes need to be weighed against viral exposure to 
patients and staff, considering each individual’s comor-
bidities and age to predict risk of mortality because of 
COVID-19. Lastly, these are only recommendations and 
are not intended to supersede individual physician judg-
ment or institutional policies and guidelines.
All efforts should be made to avoid delayed diagnosis 
in patients considered at high priority, due to the potential 
impact on cancer outcome. Suspicious symptoms, clinical 
or imaging findings are listed below:
 1. new onset of a breast palpable nodule [16];
 2. new bloody or watery, unilateral, unifocal, nipple dis-
charge [17, 18];
 3. orange peel skin [16];
 4. skin or nipple retraction [16];
 5. search for carcinoma of unknown primary (CUP) syn-
drome [19];
 6. breast abscess, hematoma, or infected seroma [20];
 7. clinical suspicion of inflammatory or locally advanced 
breast cancer [16];
 8. suspicion of breast cancer in pregnant women [21];
 9. preoperative imaging for local/contralateral staging 
[22];
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 10. imaging for monitoring the effect of neoadjuvant ther-
apy [23];
 11. recall from screening for further workup [24];
 12. indication to breast and/or loco-regional lymph node 
needle biopsy [20].
Moreover, the multidisciplinary tumor board meetings 
should be restricted to one professional for each discipline 
of the core team [25] or, better, online performed involv-
ing all the members, for cases requiring multidisciplinary 
decision (e.g., B3 lesions diagnosed on image-guided breast 
biopsy, decision to perform or not breast magnetic reso-
nance imaging (MRI) for local and contralateral staging; 
decision on type and frequency of imaging for monitoring 
the effect of neoadjuvant therapy, etc.). In the context of 
current pandemic, multidisciplinary discussions should take 
into consideration both values and preferences of any indi-
vidual patient as well as the local epidemiological condition, 
expected to strongly vary during the next months.
Personal protective equipment
The Italian College of Breast Radiologists by SIRM pro-
motes the following precautions to protect both patients 
and healthcare workers (radiologists, radiographers, nurses, 
and reception staff) from infection or disease spread dur-
ing breast imaging procedures, particularly mammography, 
breast ultrasound, breast MRI, and breast intervention pro-
cedures, such as biopsy. The close proximity of both the 
patients’ and healthcare workers’ faces during these imaging 
procedures raises concern for droplet contamination in addi-
tion to blood spatter contamination, which may occur during 
image-guided interventions and spread by saliva while talk-
ing during imaging (https ://apps.who.int/, 2020). Everyone 
involved is invited to follow the indications explained below 
during breast imaging procedures, avoiding inappropriate, 
unsolicited, or redundant examinations and being compliant 
with the established settings.
Oncological/urgent outpatient, supposed 
SARS‑CoV‑2 negative
All patients are considered at risk of SARS-CoV-2 infection. 
In the waiting room, the patient should be present alone with-
out any accompanying caregiver; close adherence to physi-
cal distancing (at least 1 m) is required between each patient. 
Patients with fever or respiratory symptoms (cough, dyspnoea, 
cold, sore throat) should be invited to go back home and con-
tact the referring physician. Asymptomatic patients should be 
invited to sanitize their hands, using the appropriate devices set 
up at the entrance of the waiting room. Patients wearing gloves 
should be invited to replace them with new ones provided by 
the center. Patients must wear a surgical mask (provided by 
the center if the patient does not wear it at the arrival), and if 
wearing an FFP2 or FFP3 mask with filter, they should wear 
a surgical mask over.
All staff having close or physical contact with patients 
undergoing breast imaging, including interventional proce-
dures (breast biopsy), should wear surgical mask, visor or gog-
gle protection, disposable gown, disposable cap, and dispos-
able gloves. For breast ultrasound, the probe should be covered 
with a probe cover or glove. All the devices with direct contact 
to the patient (e.g., ultrasound probe cover, mammographic 
equipment, magnetic resonance breast coil) should be sani-
tized with a disinfectant before every patient. The healthcare 
workers remaining 1 m from the patient may not wear special 
devices.
SARS‑CoV‑2 infection under investigation (patients 
waiting for swab result)
The patient must wear a surgical mask. All healthcare work-
ers (radiologists, radiographers, and nurses) wear an FFP2 
mask, visor or goggle protection, disposable gown, disposa-
ble cap, and disposable gloves. The ultrasound cover must be 
implemented with washable or plastic film on the keyboard 
and the ultrasound machine, not only for interventional 
procedures. The ultrasound probe cover must be changed 
for each patient to prevent potential transmission. Further 
sanitization of all the devices with which the patient comes 
into contact (e.g., ultrasound probe and machine, mammo-
graphic equipment, and magnetic resonance room) must be 
performed after undressing at the end procedure to be ready 
for next dressing.
Patients positive for SARS‑CoV‑2 infection
The patient must wear a surgical mask. All healthcare work-
ers (radiologists, radiographers, and nurses) wear an FFP2 
or FFP3 mask, visor or goggle protection, disposable water-
proof gown, disposable cap, double disposable gloves. Com-
plete coverage of the ultrasound machine and probe must be 
implemented, not only for interventional procedures. The 
probe cover must be changed for each patient to prevent 
transmission of further infection. Further sanitization of all 
the area in which the patient comes into contact must be 
performed after undressing at the end procedure to be ready 
for next dressing. In cases where the patient cannot wear the 
surgical mask, healthcare workers must wear an FFP3 mask.
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Emotional aspects of cancer patients 
during COVID‑19 pandemic
All the commotion of the COVID-19 pandemic is anxiety-
provoking among both patients and practitioners. The aim of 
these recommendations is to share good clinical practice rec-
ommendations in this difficult contest, giving the clinicians 
the cornerstones to manage patients correctly and safely. 
Oncological patient is one of the most fragile during the pan-
demic. The significant psychological impact on oncological 
patients is compounded by multiple factors: knowledge that 
the individual is at higher risk of serious complication if 
infected by SARS-CoV-2, loneliness and isolation as a result 
of social distancing, and the underlying constant fear of the 
cancer [26]. Patient psychological well-being needs to be 
considered and often can be addressed with telemedicine/
phone visits. To reduce uncertainty feelings affecting both 
clinicians and patients, structured recommendations and the 
adequate psychological support are essential tools for health-
care workers to aid cancer patients to overcome this difficult 
moment [27, 28].
Conclusions and future directions
This information should be used to provide radiologists 
with structured recommendations for breast care in both 
asymptomatic population and breast cancer patients dur-
ing the COVID-19 pandemic. In particular, we recommend 
that diagnostic procedures in symptomatic patients and 
in patients with a suspicious finding should be confirmed 
according to local availability and resources. Breast can-
cer patient’s follow-up and routine breast cancer screening 
should be performed with a delay of no more than 3 months 
from the scheduled date, compatibly with the local organi-
zational conditions. All breast imaging procedures should be 
conducted wearing personal protective equipment precau-
tions, following the measures of social distancing, and the 
sanitization of equipment and spaces to protect both patients 
and healthcare workers. However, as the pandemic rapidly 
evolves, we are increasingly learning about viral transmis-
sion and its impact on the healthcare system. Thus, these 
recommendations may change over time and could need to 
be updated. It is our hope that this paper will help women, 
radiologists, and all other clinicians to provide the highest-
level care for their patients during this evolving pandemic.
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